Refining the phenotype of Unverricht-Lundborg disease (EPM1)

Neurology

Volumn 84, Issue 15, 2015, Pages 1529-1536

  Hyppönen, Jelena ^a,b   Aïkiä, Marja ^a   Joensuu, Tarja ^d,e   Julkunen, Petro ^b   Danner, Nils ^b,f   Koskenkorva, Païvi ^c   Vanninen, Ritva ^c,f   Lehesjoki, Anna Elina ^d,e   Mervaala, Esa ^b,f   Kälviaïnen, Reetta ^a,f  

^a Neurocenter   (China)

^b Department of Clinical Neurophysiology ^*  (United Kingdom)

^c Kuopio Epilepsy Center Department of Clinical Radiology   (United Kingdom)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVARACETAM; CLOBAZAM; CLONAZEPAM; CYSTATIN B; DIAZEPAM; ETIRACETAM; LAMOTRIGINE; NITRAZEPAM; PHENOBARBITAL; PHENYTOIN; PIRACETAM; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; CSTB PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL EXAMINATION; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR CORTEX; MOTOR PERFORMANCE; MYOCLONUS; MYOCLONUS EPILEPSY; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; TONIC CLONIC SEIZURE; TRANSCRANIAL MAGNETIC STIMULATION; ADOLESCENT; CHILD; FINLAND; GENETICS; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME; UNVERRICHT-LUNDBORG SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; CHILD; CYSTATIN B; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; MOTOR CORTEX; MUTATION; MYOCLONUS; PHENOTYPE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSCRANIAL MAGNETIC STIMULATION; UNVERRICHT-LUNDBORG SYNDROME; YOUNG ADULT;

EID: 84927720794     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001466     Document Type: Article

References (40)

1. Shields WD. Diagnosis of infantile spasms, Lennox-Gastaut syndrome, and progressive myoclonic epilepsy. Epilepsia 2004;45(suppl 5):2-4.
2. Kälviaïnen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, Mervaala E. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008;49:549-556.
3. Koskiniemi M. Baltic myoclonus. Ann Clin Res 1987;19: 311-312.
4. Norio R, Koskiniemi M. Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet 1979;15:382-398.
5. Marseille Consensus Group. Classification of progressive myoclonus epilepsies and related disorders. Ann Neurol 1990;28:113-116.
6. de Haan GJ, Halley DJ, Doelman JC, et al. Univerrichtlundborg disease: underdiagnosed in the Netherlands. Epilepsia 2004;45:1061-1063.
7. Kagitani-Shimono K, Imai K, Okamoto N, Ono J, Okada S. Unverricht-Lundborg disease with cystatin B gene abnormalities. Pediatr Neurol 2002;26:55-60.
8. Kyllerman M, Sommerfelt K, Hedstrom A, Wennergren G, Holmgren D. Clinical and neurophysiological development of Unverricht-Lundborg disease in four Swedish siblings. Epilepsia 1991;32:900-909.
9. Mazarib A, Xiong L, Neufeld MY, et al. Unverricht-Lundborg disease in a five-generation Arab family: instability of dodecamer repeats. Neurology 2001;57:1050-1054.
10. Chew NK, Mir P, Edwards MJ, et al. The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases. Mov Disord 2008;23:107-113.
11. Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with selflimited progression: long-term follow-up of 20 patients. Epilepsia 2006;47:860-866.
12. Lalioti MD, Scott HS, Genton P, et al. A PCR amplification method reveals instability of the dodecamer repeat in progressive myoclonus epilepsy (EPM1) and no correlation between the size of the repeat and age at onset. Am J Hum Genet 1998;62:842-847.
13. Moulard B, Darcel F, Mignard D, et al. Founder effect in patients with Unverricht-Lundborg disease on Reunion Island. Epilepsia 2003;44:1357-1360.
14. Moulard B, Genton P, Grid D, et al. Haplotype study of West European and North African Unverricht-Lundborg chromosomes: evidence for a few founder mutations. Hum Genet 2002;111:255-262.
15. Virtaneva K, D'Amato E, Miao J, et al. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet 1997;15:393-396.
16. Pennacchio LA, Lehesjoki AE, Stone NE, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996;271:1731-1734.
17. Lalioti MD, Mirotsou M, Buresi C, et al. Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). Am J Hum Genet 1997;60:342-351.
18. Lafreniere RG, Rochefort DL, Chretien N, et al. Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nat Genet 1997;15:298-302.
19. Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 1997;386:847-851.
20. Koskenkorva P, Hyppönen J, Aïkiä M, et al. Severer phenotype in Unverricht-Lundborg disease (EPM1) patients compound heterozygous for the dodecamer repeat expansion and the c.202C.T mutation in the CSTB gene. Neurodegener Dis 2011;8:515-522.
21. Danner N, Julkunen P, Könönen M, et al. Primary motor cortex alterations in a compound heterozygous form of Unverricht-Lundborg disease (EPM1). Seizure 2011;20:65-71.
22. Danner N, Julkunen P, Khyuppenen J, et al. Altered cortical inhibition in Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1). Epilepsy Res 2009;85:81-88.
23. Danner N, Saïsänen L, Maättä S, et al. Motor cortical plasticity is impaired in Unverricht-Lundborg disease. Mov Disord 2011;26:2095-2100.
24. Koskenkorva P, Khyuppenen J, Niskanen E, et al. Motor cortex and thalamic atrophy in Unverricht-Lundborg disease: voxel-based morphometric study. Neurology 2009; 73:606-611.
25. Koskenkorva P, Niskanen E, Hyppönen J, et al. Sensorimotor, visual, and auditory cortical atrophy in Unverricht-Lundborg disease mapped with cortical thickness analysis. AJNR Am J Neuroradiol 2012;33:878-883.
26. Frucht SJ, Leurgans SE, Hallett M, Fahn S. The unified myoclonus rating scale. Adv Neurol 2002;89:361-376.
27. Joensuu T, Kuronen M, Alakurtti K, et al. Cystatin B: mutation detection, alternative splicing and expression in progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. Eur J Hum Genet 2007;15:185-193.
28. Saïsänen L, Pirinen E, Teitti S, et al. Factors influencing cortical silent period: optimized stimulus location, intensity and muscle contraction. J Neurosci Methods 2008; 169:231-238.
29. Iivanainen M, Himberg JJ. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 1982;39:236-238.
30. Canafoglia L, Gennaro E, Capovilla G, et al. Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations. Epilepsia 2012;53:2120-2127.
31. Joensuu T, Lehesjoki AE, Kopra O. Molecular background of EPM1-Unverricht-Lundborg disease. Epilepsia 2008;49:557-563.
32. Pinto E, Freitas J, Duarte AJ, et al. Unverricht-Lundborg disease: homozygosity for a new splicing mutation in the cystatin B gene. Epilepsy Res 2012;99:187-190.
33. Larson GP, Ding S, Lafreniere RG, Rouleau GA, Krontiris TG. Instability of the EPM1 minisatellite. Hum Mol Genet 1999;8:1985-1988.
34. Alakurtti K, Virtaneva K, Joensuu T, Palvimo JJ, Lehesjoki AE. Characterization of the cystatin B gene promoter harboring the dodecamer repeat expanded in progressive myoclonus epilepsy, EPM1. Gene 2000;242: 65-73.
35. Lalioti MD, Scott HS, Antonarakis SE. Altered spacing of promoter elements due to the dodecamer repeat expansion contributes to reduced expression of the cystatin B gene in EPM1. Hum Mol Genet 1999;8:1791-1798.
36. Cheeran B, Talelli P, Mori F, et al. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol 2008;586:5717-5725.
37. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-1109.
38. Kaddurah AK, Holmes GL, Genton P, Gelisse P, Thomas P, Dravet C. Possible precipitation of myoclonic seizures with oxcarbazepine. Epilepsy Behav 2006;8: 289-293.
39. Ziemann U. TMS and drugs. Clin Neurophysiol 2004; 115:1717-1729.
40. Danner N, Julkunen P, Hyppönen J, et al. Alterations of motor cortical excitability and anatomy in Unverricht-Lundborg disease. Mov Disord 2013;28:1860-1867.